Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in France / NCT03283852
Recruiting Observational

Identifying New Genetic Causes to Development Disorders

NCT03283852 · tracked via the Priya Life Science France tracker
Sponsor
Fondation Ophtalmologique Adolphe de Rothschild
Phase
Observational
Started
2017-02-21
Last updated
2024-06-05

Condition(s) studied

Disorders of Sex DevelopmentGrowth DisordersPuberty Disorders

Investigational drug(s) / intervention(s)

blood sample

blood sample: search for genetic mutations

Study summary

Disorders of growth, puberty and sex development can have genetic causes. The exome analysis could detect new mutations responsible for these disorders and the frequency of these mutations in these disorders, their association with other malformations.

Eligibility

Sex
ALL
Min age
—
Max age
—
Healthy volunteers
No
Inclusion Criteria: * congenital growth hormone deficiency * puberty disorder * gonadal dysgenesis or anorchia * primary ovarian failure * disorder of sex development * subjects related to a patient with one of the above criteria Exclusion Criteria: * environmental or auto-immune cause

Primary outcome measure(s)

  • mutation research — baseline
    frequency of genetic mutation

Trial sites (1)

FacilityCityRegionStatus
Hôpital Fondation A de Rothschild Paris France Recruiting

More Fondation Ophtalmologique Adolphe de Rothschild trials in France

Cardiac Involvement in Wilson's Disease Recruiting
Optimization of Sequences to Improve the Quality and Comfort of the Magnetic Resonance Imaging Examination Recruiting
Limbal Stem Cell Deficiency of Genetic Origin: Genotype-phenotype Correlation Recruiting
RESting-state Functional MRI for Prediction of Post-surgical Prognosis In Pediatric Drug-Resistant Epilepsy Recruiting
Detection and Management of Sinusitis in a Single-center Prospective Cohort of Patients With Exudative AMD (SINE) Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT03283852 on ClinicalTrials.gov ↗ ← All trials in France